Claims for Patent: 9,526,710

Summary for Patent: 9,526,710

Title:	Treatment and diagnosis of melanoma
Abstract:	The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
Inventor(s):	Tavazoie; Sohail (New York, NY), Pencheva; Nora (New York, NY)
Assignee:	THE ROCKEFELLER UNIVERSITY (New York, NY)
Application Number:	14/486,477
Patent Claims:	1. A method of treating metastatic melanoma in a subject in need thereof, said method comprising administering to the subject an LXR.beta. agonist selected from: ##STR00020## or a pharmaceutically acceptable salt thereof in an amount sufficient to suppress metastatic progression of said melanoma. 2. The method of claim 1, wherein said metastatic melanoma is resistant to vemurafenib and/or dacarbazine. 3. The method of claim 1, wherein said LXR.beta. agonist is compound 1, or a pharmaceutically acceptable salt thereof. 4. The method of claim 1, wherein said LXR.beta. agonist is compound 2, or a pharmaceutically acceptable salt thereof. 5. The method of claim 1, wherein said LXR.beta. agonist is compound 12, or a pharmaceutically acceptable salt thereof. 6. The method of claim 1, wherein said LXR.beta. agonist is compound 25, or a pharmaceutically acceptable salt thereof. 7. The method of claim 1, wherein said metastatic melanoma is resistant to dacarbazine, a BRAF inhibitor, a MEK inhibitor, a CTLA-4 inhibitor, a PD-1 inhibitor and/or a PD-L1 inhibitor. 8. The method of claim 1, wherein the method does not comprise further concurrently administering to the subject an antiproliferative agent. 9. The method of claim 1, wherein said method further comprises administration of an additional anticancer therapy. 10. The method of claim 9, wherein said additional anticancer therapy is an antiproliferative. 11. The method of claim 10, wherein said antiproliferative is a PD1 inhibitor, a VEGF inhibitor, a VEGFR2 inhibitor, a CTLA4 inhibitor, and/or a PDL1 inhibitor. 12. The method of claim 10, wherein said antiproliferative is a PD-1 inhibitor or a PD-L1 inhibitor. 13. The method of claim 10, wherein said antiproliferative is nivolumab, ipilmumab, dacarbazine, or vemurafenib. 14. The method of claim 1, wherein said method comprises suppressing metastatic colonization of the melanoma to the lung and/or the brain.

Details for Patent 9,526,710

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	12/22/2014		2032-08-13
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	10/04/2017		2032-08-13
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	08/27/2021		2032-08-13